Ropanicant

DB19134InvestigationalSmall molecule

Ropanicant is under investigation in clinical trial NCT06126497 (Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients).

Mechanism: Pharmacologically active on Neuronal acetylcholine receptor subunit alpha-4 and Neuronal acetylcholine receptor subunit beta-2
Curator reviewed
Formula / weight: C₁₁H₁₃ClN₂O · 224.69 g/mol (avg)
Also known as: (1r,3s,5r)-3-(((6-chloropyridin-3-yl)oxy)methyl)-2-azabicyclo(3.1.0)hexane · 2-azabicyclo(3.1.0)hexane, 3-(((6-chloro-3-pyridinyl)oxy)methyl)-, (1r,3s,5r)- · Ropanicant, (+)-
Code names: SUVN-911 · SUVN-911 free base

Resolves to

Compound

Structure

InChIKeyPYSCVJMLJRHJGJ-OYNCUSHFSA-NSMILESClC1=CC=C(OC[C@@H]2C[C@H]3C[C@H]3N2)C=N1

Targets

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ropanicant, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.